Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01597063 · ClinicalTrials.gov registry record
Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 3,333
- Enrollment target
NCT01597063: Completed study, sponsored by Sequenom.
NCT01597063 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 3,333 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01597063 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 3,333 participants
- Enrollment target
Study Summary
Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled. Study blood will be collected in the first or second trimester at a scheduled prenatal screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will be followed until delivery and the birth outcome recorded.
Interventions
- DEVICE SEQureDx Trisomy Test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,333 participants |
| Start Date | 2012-07 |
| Est. Completion | 2015-12 |
What the finished NCT01597063 record still lists
NCT01597063 is an observational study that tracks outcomes without assigning an intervention. Its 3,333 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which SEQureDx Trisomy Test is the first listed.
NCT01597063 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01597063 about?
NCT01597063 is a clinical study titled "Clinical Evaluation of the SEQureDx Trisomy Test in Low Risk Pregnancies". Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled. Study blood will be collected in the first or second trimester at a scheduled prenatal screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will be followed until delivery and...
What is the current status of trial NCT01597063?
This trial is currently completed. The enrollment target is 3,333 participants. The study started on 2012-07. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01597063?
The interventions under investigation include: SEQureDx Trisomy Test (DEVICE).
Who is sponsoring clinical trial NCT01597063?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
- NCT07214610 · 3,300 participants · NA
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT06815536 · 3,291 participants
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia